A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Public ClinicalTrials.gov record NCT02922764. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.
Study identification
- NCT ID
- NCT02922764
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 146 participants
Conditions and interventions
Conditions
Interventions
- RGX-104 Drug
- Ipilimumab Drug
- Docetaxel Drug
- Pembrolizumab Drug
- Carboplatin Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1, 2016 (Actual)
- Primary completion
- Jan 22, 2025 (Actual)
- Completion
- Jan 22, 2025 (Actual)
- Last update posted
- Mar 26, 2025
2016 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology | Tucson | Arizona | 85711 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| Florida Cancer Specialist | Lake Mary | Florida | 32799 | — |
| Comprehensive Hematology Oncology | St. Petersburg | Florida | 33709 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Maryland Oncology | Columbia | Maryland | 21044 | — |
| Regions Hospital | Saint Paul | Minnesota | 55101 | — |
| Dartmouth Hitchcock Medical | Lebanon | New Hampshire | 03756 | — |
| CINJ | New Brunswick | New Jersey | 08901 | — |
| Quantum Santa Fe | Santa Fe | New Mexico | 87505 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health Sciences University | Portland | Oregon | 97239 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02922764, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02922764 live on ClinicalTrials.gov.